Rapamycin is an immunosuppressive drug with two FDA-approved uses: preventing organ rejection in kidney transplant patients aged 13 and older, and treating a rare lung disease called lymphangioleiomyomatosis (LAM). But the drug has attracted enormous attention beyond these approved uses, particularly for its potential to slow aging, and modified versions of it are used in cancer treatment. Here’s what rapamycin does, where it comes from, and why researchers are so interested in it.
How Rapamycin Works in the Body
Rapamycin targets a protein called mTOR (mechanistic target of rapamycin), which acts as a central switch for cell growth, division, and metabolism. When nutrients are plentiful, mTOR signals cells to grow and multiply. Rapamycin blocks this signal by binding to one of mTOR’s two complexes, called mTORC1, and preventing it from recruiting the molecules it needs to function. This binding is irreversible.
mTOR also forms a second complex, mTORC2, which rapamycin doesn’t directly block. However, prolonged rapamycin exposure can suppress mTORC2 activity indirectly by sequestering the mTOR protein itself. This dual suppression is part of what makes rapamycin so powerful, and also why its effects are so wide-ranging. By dialing down mTOR signaling, rapamycin slows cell proliferation, reduces inflammation, and triggers cellular cleanup processes that remove damaged components.
Preventing Kidney Transplant Rejection
Rapamycin’s primary clinical role is keeping the immune system from attacking a transplanted kidney. After a transplant, the body recognizes the new organ as foreign and mounts an immune response to destroy it. Rapamycin suppresses the growth and activation of T cells, the immune cells responsible for this rejection response.
Transplant patients typically start with a higher loading dose on the first day, then transition to a lower daily maintenance dose that they continue long-term. Doctors monitor drug levels in the blood closely to keep them within a therapeutic range, since too little means the organ is at risk of rejection and too much raises the likelihood of side effects. The target blood levels and dosing vary depending on whether a patient is considered low, moderate, or high risk for rejection.
Treating Lymphangioleiomyomatosis
LAM is a rare progressive lung disease that almost exclusively affects women, typically of childbearing age. Abnormal smooth muscle-like cells proliferate in the lungs, forming cysts and gradually destroying lung tissue. Because these cells depend on mTOR signaling to grow, rapamycin can slow their proliferation and stabilize lung function. This is rapamycin’s second FDA-approved indication, and for many LAM patients it has been a meaningful treatment option where few previously existed.
Cancer Treatment With Modified Versions
Rapamycin itself isn’t widely used as a cancer drug, but chemically modified versions called rapalogs are. Two of these, everolimus and temsirolimus, are approved for treating several cancers: advanced kidney cancer that has spread, certain breast cancers, and neuroendocrine tumors (cancers that arise from hormone-producing cells). These drugs work on the same principle as rapamycin, blocking mTOR to starve tumor cells of growth signals. Research also suggests that part of their effectiveness comes from boosting the immune system’s ability to recognize and attack tumors, not just from directly slowing cancer cell growth.
The Aging and Longevity Connection
Rapamycin is arguably the most talked-about drug in longevity science. The logic is straightforward: mTOR drives growth, and growth that continues unchecked is linked to the biological processes of aging. By turning mTOR down, rapamycin may mimic some of the cellular benefits of caloric restriction, which is one of the most consistent ways to extend lifespan in animal studies.
A systematic review published in The Lancet Healthy Longevity found that rapamycin and its derivatives improved age-related measures across the immune, cardiovascular, and skin systems in human studies. One of the more striking findings involved the immune system: randomized controlled trials showed that giving rapamycin derivatives alongside flu vaccines boosted the immune response in older adults, essentially reversing some of the immune decline that comes with age. This is counterintuitive for a drug classified as an immunosuppressant, and it highlights how lower doses of rapamycin may fine-tune immune function rather than simply suppress it.
Not every result has been positive. In healthy individuals, eight weeks of low-dose rapamycin (1 mg per day) showed no effect on cognitive function. Studies in age-related macular degeneration, a common cause of vision loss in older adults, produced mixed results: one trial showed reduced retinal thickening at 6 and 12 months, while a longer 24-month trial found no meaningful difference compared to placebo in preventing the progression of the disease.
Alzheimer’s Disease Research
One of the more closely watched trials is testing rapamycin in people with mild cognitive impairment or early-stage Alzheimer’s disease. This Phase 2 trial, which began in August 2021 and is expected to run through March 2026, is giving 40 participants either daily rapamycin or a placebo for one year, followed by six months of monitoring. Researchers are tracking cognitive and daily functioning alongside brain imaging with MRI and PET scans to look for structural and metabolic changes. The trial is small, designed primarily to assess safety and gather early signals rather than prove effectiveness, but it represents a serious step toward understanding whether mTOR inhibition could slow neurodegeneration in humans.
Side Effects and Drug Interactions
Rapamycin’s side effects reflect how broadly mTOR influences the body. At the doses used for transplant patients, common issues include mouth sores, elevated cholesterol and triglycerides, increased blood sugar, and a higher susceptibility to infections. These effects are dose-dependent, which is why the longevity community has focused on whether much lower or intermittent dosing could deliver benefits while minimizing risks.
Rapamycin is metabolized by an enzyme system in the liver and gut called CYP3A4, which also processes a large number of other medications. Drugs that inhibit this enzyme can cause rapamycin levels to spike, increasing toxicity risk, while drugs that activate it can drop rapamycin below effective levels. This makes drug interactions a serious concern, especially for transplant patients who take multiple medications simultaneously. Rapamycin itself can also alter how the body processes other drugs through this same pathway, creating a two-way interaction problem.
Where Rapamycin Comes From
Rapamycin has one of the more colorful origin stories in pharmacology. In 1964, a Canadian medical expedition traveled to Easter Island (known as Rapa Nui in the local language) to study the health of its inhabitants. A microbiologist named Georges Nógrády collected soil samples from around the island, hoping to find compounds that might explain why the local population appeared resistant to tetanus despite walking barefoot in soil teeming with bacteria. From one of those samples, researchers later isolated a soil bacterium called Streptomyces hygroscopicus, which produced a compound with potent antifungal properties. They named it rapamycin after the island. It was only later that scientists discovered its immunosuppressive and anti-proliferative effects, which turned out to be far more medically significant than its antifungal activity.